Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553450 | 1.00 | HDAC1 (0.42) | HDAC1HDAC6NOTUMNR1H2PRMT5 | |
| SCHEMBL4666060 | 0.92 | NOTUM (0.43) | HDAC1HDAC6NOTUMNR1H2PRMT5 | |
| SCHEMBL2109995 | 0.87 | NOTUM (0.46) | NOTUMNR1H2PRMT5WDR77ALDH1A1 | |
| SCHEMBL10211390 | 0.87 | NOTUM (0.46) | NOTUMNR1H2PRMT5WDR77ALDH1A1 | |
| SCHEMBL619483 | 0.86 | MEN1 (0.48) | NOTUMMEN1KMT2AALDH1A1 | |
| SCHEMBL5016207 | 0.82 | NOTUM (0.46) | NOTUMPRMT5WDR77MEN1KMT2A | |
| SCHEMBL1270489 | 0.81 | PTGER4 (0.52) | HDAC1HDAC6 | |
| SCHEMBL3902271 | 0.81 | CNR2 (0.52) | NOTUMNR1H2ALDH1A1ESR2UCHL1 | |
| SCHEMBL23293654 | 0.80 | NR1H2 (0.46) | NOTUMNR1H2PRMT5WDR77MEN1 | |
| SCHEMBL16123405 | 0.80 | UCHL1 (0.51) | NOTUMNR1H2PRMT5WDR77MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025807-A1 | CD38 INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025807-A1 | CD38 INHIBITORS | CD38, GLS, IDH2 | HDAC1 377/4885HDAC6 469/4885NOTUM 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.